

Peristiwa Penting Important Events



2022
3 Februari
3 February

KOLABORASI MES DENGAN BIO FARMA DAN RNI (ID FOOD) TUMBUHKAN WIRAUSAHA MUDA SYARIAH DI INDONESIA

PT Bio Farma (Persero) bersama PT Rajawali Nusantara Indonesia (Persero) atau ID Food berkerja sama dengan Masyarakat Ekonomi Syariah (MES) berkolaborasi menyelenggarakan Seminar Nasional Wirausaha Muda Syariah dengan tema "Pengembangan Ekonomi Syariah kepada Wirausaha Muda dalam Mendukung Keberlanjutan dan Kemandirian" dalam rangka meningkatkan minat wirausaha yang masih berkisar 3,47 persen dari total penduduk Indonesia.

COLLABORATION BETWEEN MES, BIO FARMA, AND RNI (ID FOOD) TO FOSTER YOUNG SHARIA ENTREPRENEURS IN INDONESIA

PT Bio Farma (Persero) and PT Rajawali Nusantara Indonesia (Persero) or ID Food collaborated with the Islamic Economic Society (MES) to organize the National Seminar for Young Sharia Entrepreneurs on the theme of "Developing Sharia Economy for Young Entrepreneurs to Support Sustainability and Independence." The seminar aimed to increase the interest of entrepreneurs, which is still around 3.47 percent of Indonesia's total population.



2022
23 Februari
February 23

BIO FARMA AKAN TERIMA TEKNOLOGI TRANSFER VAKSIN mRNA

Indonesia melalui Induk Holding BUMN Farmasi Bio Farma, dipastikan akan mampu membuat vaksin terbaru dengan platform teknologi mRNA setelah ditunjuk oleh Badan Kesehatan Dunia (WHO) sebagai negara yang akan membangun hub, atau pusat produksi vaksin COVID-19 berbasis messenger RNA (mRNA) di kawasan Asia Tenggara.

BIO FARMA TO RECEIVE mRNA VACCINE TECHNOLOGY TRANSFER

Indonesia, through the Holding SOE Pharmaceutical Bio Farma, has been designated by the World Health Organization (WHO) to build a hub, or production center, for COVID-19 vaccines based on messenger RNA (mRNA) technology in Southeast Asia. Indonesia is expected to produce the latest vaccine with mRNA platform technology.



2022
24 Maret
March 24

BIO FARMA BERPARTISIPASI PADA RANGKAIAN KEGIATAN WORKING GROUP MEETING G20 DI YOGYAKARTA

Bio Farma sebagai BUMN Farmasi mendukung rangkaian kegiatan presidensi G20 di Indonesia, salah satunya kegiatan *Environment Deputies Meeting and Climate Sustainability Working Group* yang diselenggarakan di Yogyakarta pada tanggal 21 hingga 24 Maret 2022.

BIO FARMA PARTICIPATES IN G20 WORKING GROUP MEETING IN YOGYAKARTA

As a SOE Pharmaceutical company, Bio Farma supported the G20 presidency activities in Indonesia, including the Environment Deputies Meeting and Climate Sustainability Working Group held in Yogyakarta from March 21 to 24, 2022.



2022
27 April
April 27

RAYAKAN HARI RAYA TANPA RASA RISAU DENGAN VAKSINASI BOOSTER

Untuk mendukung kegiatan mudik di momen Lebaran tahun 2022 yang sehat dan aman, Bio Farma menyelenggarakan program vaksinasi booster bagi para calon pemudik. Vaksin booster yang digunakan, yakni Sinovac atau Coronavac PT Bio Farma, Pfizer, AstraZeneca, Moderna, Zifivax dan Sinopharm.

CELEBRATE EID WITHOUT WORRY WITH BOOSTER VACCINATION

To support healthy and safe travel during the Eid al-Fitr holiday season in 2022, Bio Farma organized a booster vaccination program for prospective travelers. The booster vaccines used were Sinovac or Coronavac from PT Bio Farma, Pfizer, AstraZeneca, Moderna, Zifivax, and Sinopharm.



2022

11 Mei
May 11

BIO FARMA BERSAMA MDI VENTURES MELUNCURKAN BIO-HEALTH FUND

Bio Farma Bersama MDI Ventures, perusahaan modal ventura miliki PT Telekomunikasi Indonesia TBK, meluncurkan Bio-Health Fund, yaitu sebuah badan investasi yang melakukan pendanaan untuk menangkap peluang pertumbuhan pada sektor Biotek dan Layanan Kesehatan.

BIO FARMA AND MDI VENTURES LAUNCH BIO-HEALTH FUND

Bio Farma and MDI Ventures, a venture capital company owned by PT Telekomunikasi Indonesia TBK, launched Bio-Health Fund, an investment fund that provides funding to capture growth opportunities in the biotech and healthcare service sectors.



2022

2 Juni
June 2

BIO FARMA RESMIKAN PABRIK BARU BAHAN BAKU OBAT POVIDONE IODINE

Peresmian fasilitas produksi bersamaan dengan adanya Kick Off Change Source penggunaan bahan baku obat dalam negeri.

BIO FARMA INAUGURATES NEW FACTORY FOR POVIDONE IODINE DRUG RAW MATERIAL

The production facility was inaugurated alongside the kick-off of the change source initiative for the use of domestic drug raw materials.



2022

25 Mei
May 25

BIO FARMA JADI OBSERVER UNESCO GLOBAL GEOPARK NETWORK PADA REVALIDASI CILETUH PELABUHANRATU UNESCO GLOBAL GEOPARK NETWORK (CPUUGGP)

Bio Farma menjadi korporasi pioneer dalam mendukung dan terlibat aktif dalam pengembangan Geopark di Asia juga menjadi contoh pelibatan sektor usaha pada pengembangan Geopark.

BIO FARMA BECOMES OBSERVER OF UNESCO GLOBAL GEOPARK NETWORK ON THE REVALIDATION OF CILETUH PELABUHANRATU UNESCO GLOBAL GEOPARK NETWORK (CPUUGGP)

Bio Farma became a pioneer corporation in supporting and actively participating in the development of Geoparks in Asia and served as an example of the involvement of the business sector in the development of Geoparks.



2022

9 Juni
June 9

BIO FARMA MENGINISIASI UJI KLINIS FASE 3 VAKSIN COVID-19 BUMN

Awal uji klinis ditandai dengan kick-off penyuntikan vaksin di Lab Sentral RSND Universitas Diponegoro.

BIO FARMA INITIATES PHASE 3 CLINICAL TRIALS FOR BUMN COVID-19 VACCINE

The clinical trials began with the kick-off of vaccine injections at the RSND University of Diponegoro Central Lab.



2022
2 Juli
July 2

BIO FARMA BERKOLABORASI DENGAN GOOGLE CLOUD DAN 'CONNECTEDLIFE WITH FITBIT' UNTUK MEMBERDAYAKAN HIDUP LEBIH SEHAT DAN PENCEGAHAN PENYAKIT KRONIS DI SELURUH INDONESIA

Kerjasama pengembangan "ConnectedLife with Fitbit," suatu platform virtual kesehatan, yang dibuat sesuai kebutuhan individu, yang pertama dari jenisnya secara lokal. Tujuannya adalah untuk menciptakan masyarakat Indonesia yang lebih sehat melalui pencegahan penyakit kronis.

BIO FARMA COLLABORATES WITH GOOGLE CLOUD AND 'CONNECTEDLIFE WITH FITBIT' TO EMPOWER HEALTHIER LIVES AND PREVENT CHRONIC DISEASES THROUGHOUT INDONESIA

The partnership involves the development of "ConnectedLife with Fitbit," a virtual health platform tailored to individual needs and the first of its kind locally. The aim is to create a healthier Indonesian society through chronic disease prevention.



2022
6 Juli
July 6

BIO FARMA MENYEPAKATI KERJASAMA DENGAN GOOGLE CLOUD, FITBIT, DAN CONNECTEDLIFE

Kesepakatan ditujukan untuk membentuk inisiatif Kesehatan digital baru yang disebut "Preventive Care Medwell" dalam rangka mendukung program pemerintah mewujudkan cetak biru dan visi Indonesia Sehat.

BIO FARMA AGREES TO PARTNERSHIP WITH GOOGLE CLOUD, FITBIT, AND CONNECTEDLIFE

The agreement is intended to form a new digital health initiative called "Preventive Care Medwell" to support the government's blueprint and vision for a healthy Indonesia.



2022
18 Juli
July 18

Bio Farma memperoleh Licensi Lembaga Sertifikat Profesi (LSP-P2) untuk bidang sertifikasi Biopharmaceutical dari BNSP (Badan Nasional Sertifikasi Profesi).
Bio Farma Obtains Professional Certification License (LSP-P2) for Biopharmaceutical Certification from BNSP (National Profession Standardization Agency).



2022
19 Juli
July 19

BIO FARMA MELUNCURKAN PRODUK KIT PCR DIAGNOSTIC BIOCOLOMELT-DX

Kit diagnostik molekuler ini digunakan untuk mendeteksi kelainan genetik yang terutama terjadi pada pasien kanker kolorektal.

BIO FARMA LAUNCHES BIOCOLOMELT-DX PCR DIAGNOSTIC KIT

The molecular diagnostic kit is used to detect genetic abnormalities, primarily in patients with colorectal cancer.



2022
22 Juli
July 22

PERESMIAN HEALTHCARE INFORMATION EXCHANGE

Peresmian Program ini ditandai dengan Kick Off dan penandatanganan PKS dan NDA oleh Bio Farma dan 3 BUMN lainnya.

INAUGURATION OF THE HEALTHCARE INFORMATION EXCHANGE

The program's inauguration was marked by the kick-off and signing of a Cooperation Agreement (PKS) and NDA by Bio Farma and three other SOEs.



2022
5 Agustus
August 5

BIO FARMA MELUNCURKAN BUKU “KONTRIBUSI UNTUK NEGERI DI MASA PANDEMI”

Bertepatan dengan hari jadi ke-132, Bio Farma meluncurkan buku buku “Kontribusi untuk Negeri di Masa Pandemi”, menceritakan seluk beluk perjalanan Bio Farma dalam mengatasi pandemi COVID-19.

BIO FARMA LAUNCHES BOOK “CONTRIBUTIONS TO THE NATION IN THE PANDEMIC ERA”

Coinciding with its 132nd anniversary, Bio Farma launched the book “Contributions to the Nation in the Pandemic Era,” detailing the company’s journey in tackling the COVID-19 pandemic.



2022
26 Agustus
August 26

DORONG KEMANDIRIAN INDUSTRI SEDIAAN FARMASI DAN ALKES, BIO FARMA PERKUAT KOLABORASI PENGEMBANGAN PRODUK

Bio Farma menjalin kolaborasi dengan perusahaan rintisan bioteknologi Nusantics, mengembangkan Bio Saliva, alat uji untuk mendeteksi COVID-19 dengan metode kumur (*gargling*). Kerjasama ini dilakukan untuk mempercepat kemandirian sediaan farmasi dan alkes.

ENCOURAGING INDEPENDENCE IN THE PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRY, BIO FARMA STRENGTHENS PRODUCT DEVELOPMENT COLLABORATION

Bio Farma has partnered with biotechnology start-up Nusantics to develop Bio Saliva, a COVID-19 testing tool using gargling as a method. The collaboration is aimed at accelerating the independence of the pharmaceutical and medical device industry.



2022
24 Agustus
August 24

BIO FARMA MENERIMA SERTIFIKAT INDI 4.0

Kemenperin memberikan nilai 3,00 level 3 pada Bio Farma berkat upaya percepatan implementasi Industri 4.0 yang mendukung industri inklusi dan berkelanjutan.

BIO FARMA RECEIVES INDI 4.0 CERTIFICATE

The Ministry of Industry gave Bio Farma a level 3 score of 3.00 for its efforts in accelerating the implementation of Industry 4.0, which supports inclusive and sustainable industries.



2022
8 September
September 8

SIAP PRODUKSI INDOVAC, MILESTONE BIO FARMA UNTUK MEMPERKUAT KEMANDIRIAN SEKTOR FARMASI INDONESIA

Bekerjasama dengan Baylor College of Medicine (BCM) Amerika Serikat, Bio Farma berhasil mengembangkan vaksin IndoVac dengan platform protein rekombinan sub-unit berbasis ragi (*yeast based*). Saat ini IndoVac telah melakukan uji klinis fase 1 dan 2, serta dalam proses uji klinis fase 3 untuk usia 18 tahun ke atas.

READY TO PRODUCE INDOVAC, A MILESTONE FOR BIO FARMA TO STRENGTHEN THE INDEPENDENCE OF THE INDONESIAN PHARMACEUTICAL SECTOR

In collaboration with Baylor College of Medicine (BCM) in the United States, Bio Farma has successfully developed the IndoVac vaccine with a yeast-based recombinant protein sub-unit platform. IndoVac has completed phase 1 and 2 clinical trials and is currently undergoing phase 3 clinical trials for ages 18 and up.



2022
15 September
September 15


BIO FARMA GANDENG CEPI, BERSIAP HADAPI PANDEMI DI MASA MENDATANG

Bio Farma, mengadakan pertemuan bersama para pemimpin Coalition for Epidemic Preparedness Innovations (CEPI). CEPI merupakan kemitraan global inovatif antara organisasi publik, swasta, filantropi, dan masyarakat sipil, untuk mengembangkan vaksin sebagai persiapan menghadapi pandemi dan epidemis.

BIO FARMA COLLABORATES WITH CEPI, PREPARED TO FACE FUTURE PANDEMICS

Bio Farma held a meeting with the leaders of the Coalition for Epidemic Preparedness Innovations (CEPI). CEPI is an innovative global partnership between public organizations, private companies, philanthropies, and civil society to develop vaccines in preparation for pandemics and epidemics.



2022
13 Oktober
October 13


PRESIDEN JOKOWI LUNCURKAN VAKSIN INDOVAC KARYA PENELITI BIO FARMA

Vaksin IndoVac untuk vaksinasi primer (dosis 1 & 2) untuk usia dewasa (18+) telah mendapatkan *use emergency authorization* (EUA) atau izin penggunaan dari Badan Pengawasan Obat dan Makanan (BPOM) pada 24 September 2022.

Turut mendampingi Presiden dalam kesempatan tersebut yaitu Menteri Koordinator Bidang Kemaritiman dan Investasi, Menteri BUMN, Menteri Kesehatan, Menteri Perhubungan, Gubernur Jawa Barat, Wali Kota Bandung dan Dirut Bio Farma.



2022
30 September
30 September


BIO FARMA JALIN KERJASAMA DENGAN PROFACTOR PHARMA LTD DARI INGGRIS

Bio Farma akan mendapat hak eksklusif untuk pengembangan bersama Blood Product Recombinant Factor VIII (rF-VIII) secara global.

BIO FARMA PARTNERS WITH PROFACTOR PHARMA LTD FROM THE UK

Bio Farma will have exclusive rights for the global development of Blood Product Recombinant Factor VIII (rF-VIII).

PRESIDENT JOKOWI LAUNCHES THE INDOVAC VACCINE DEVELOPED BY BIO FARMA RESEARCHERS

The IndoVac vaccine for primary vaccination (dose 1 & 2) for adults (18+) received emergency use authorization (EUA) from the Indonesian Food and Drug Administration (BPOM) on September 24, 2022.

President Jokowi was accompanied by the Coordinating Minister for Maritime Affairs and Investment, the Minister of State-Owned Enterprises, the Minister of Health, the Minister of Transportation, the Governor of West Java, the Mayor of Bandung, and the CEO of Bio Farma.



2022
20 Oktober
October 20

BIO FARMA TEKEN MOU DENGAN EMPAT PERUSAHAAN GLOBAL PADA G20 SOE CONFERENCE 2022

1. Dengan Suzhou Ronnsi Pharma Co., Ltd (Ronsi), terkait kerjasama pengembangan Supply Agreement Active Pharmaceutical Ingredients (API) untuk produk Enoxaparin dari Ronsi.
2. Dengan ConnectedLife Health Singapore, berupa kerjasama komersialisasi layanan preventif care di Indonesia.
3. Dengan Asuransi Jiwa InHealth Indonesia, mengenai pengembangan layanan preventive care system untuk memonitor kesehatan dan aktivitas fisik peserta MANDIRI INHEALTH menggunakan layanan Medwelldan layanan Homecare.
4. Dengan Pantai Premier Pathology Sdn Bhd, mengenai kerjasama pendampingan dan dukungan pengetahuan teknis untuk pengembangan layanan laboratorium.

BIO FARMA SIGNS MOU WITH FOUR GLOBAL COMPANIES AT THE G20 SOE CONFERENCE 2022

1. With Suzhou Ronnsi Pharma Co., Ltd (Ronsi), regarding a supply agreement for the development of Active Pharmaceutical Ingredients (API) for Enoxaparin products from Ronsi.
2. With ConnectedLife Health Singapore, for the commercialization of preventive care services in Indonesia.
3. With InHealth Indonesia Life Insurance, regarding the development of preventive care systems to monitor the health and physical activity of MANDIRI INHEALTH participants using Medwell and Homecare services.
4. With Pantai Premier Pathology Sdn Bhd, regarding technical support and knowledge transfer for the development of laboratory services.



2022
24 Oktober
October 24

SERTIFIKAT MERK VAKSIN COVID BIO FARMA

Vaksin COVID-19 produksi Bio Farma-IndoVac, resmi mendapatkan sertifikat merek dari Direktorat Kekayaan Intelektual.

BIO FARMA OBTAINS COVID VACCINE TRADEMARK CERTIFICATE

Bio Farma-IndoVac's COVID-19 vaccine officially receives a trademark certificate from the Directorate of Intellectual Property.



2022
31 Oktober
October 31

KONSISTEN TINGKATKAN PERSENTASE TKDN, BIO FARMA RAIH PENGHARGAAN ANUGERAH CINTA INDONESIA 2022

Bio Farma mendapatkan apresiasi berupa penghargaan dalam ajang "Anugerah Cinta Indonesia (ACI) 2022". Bio Farma terpilih menjadi yang terbaik di Sektor Kesehatan. Produksi vaksin Indovac, sebagai contoh, secara total bisa mencatatkan TKDN sampai 90%.

CONSISTENTLY IMPROVING TKDN PERCENTAGE, BIO FARMA RECEIVES ANUGERAH CINTA INDONESIA 2022 AWARD

Bio Farma receives appreciation in the form of an award at the "Anugerah Cinta Indonesia (ACI) 2022" event. Bio Farma is chosen as the best in the healthcare sector. For example, the production of Indovac vaccine can achieve a TKDN percentage of up to 90%.



2022
13 November
November 13

KERJA SAMA BIO FARMA GROUP DENGAN INDONESIA INVESTMENT AUTHORITY ("INA")

BUMN Farmasi PT Bio Farma (Persero) ("Bio Farma"), PT Kimia Farma Tbk ("KAEF") dan PT Kimia Farma Apotek ("KFA") menandatangi kerja sama strategis dengan Indonesia Investment Authority ("INA").

Kemitraan transformatif ini sejalan dengan tujuan Pemerintah Indonesia untuk lebih mengembangkan industri healthcare serta membawanya menuju kualitas dan standar internasional.

BIO FARMA GROUP COLLABORATES WITH INDONESIA INVESTMENT AUTHORITY ("INA")

State-owned pharmaceutical company PT Bio Farma (Persero) ("Bio Farma"), PT Kimia Farma Tbk ("KAEF"), and PT Kimia Farma Apotek ("KFA") signed a strategic partnership with the Indonesia Investment Authority ("INA").

This transformative partnership is in line with the Indonesian Government's goal of further developing the healthcare industry and bringing it towards international standards and quality.



BIO FARMA BESERTA PAVILIUN INDONESIA PERDANA HADIR DAN BERPARTISIPASI DI MEDICA 2022

MEDICA 2022 merupakan pameran alat kesehatan terbesar di dunia pada tanggal 14-17 November 2022 di Dusseldorf, Jerman. Medica 2022 diikuti lebih dari 5.000 perusahaan multinasional dengan lebih dari 15.000 jenis produk alat kesehatan.

BIO FARMA, ALONG WITH THE INDONESIAN PAVILION, PARTICIPATES IN MEDICA 2022

MEDICA 2022, the world's largest medical equipment exhibition, takes place on November 14-17, 2022, in Dusseldorf, Germany. MEDICA 2022 is attended by more than 5,000 multinational companies with over 15,000 types of medical equipment products.



BIO FARMA MELUNCURKAN PRODUK ALAT TEST ANTIBODI COVID-19, FASTBIO-RBD 2019-NCOV NEUTRALIZING ANTIBODY TEST & FASTBIO-RBD FIA METER

Pasca pemberian Vaksin COVID-19 FastBio-RBD menggunakan teknologi fluorescence immunoassay sehingga dapat memberikan hasil yang akurat dan spesifik terhadap perhitungan jumlah antibody SARS COV-2.

BIO FARMA LAUNCHES FASTBIO-RBD 2019-NCOV NEUTRALIZING ANTIBODY TEST & FASTBIO-RBD FIA METER, A COVID-19 ANTIBODY TEST TOOL

FastBio-RBD, which uses fluorescence immunoassay technology, provides accurate and specific results for the count of SARS COV-2 antibodies, post the administration of COVID-19 vaccine.



PRESIDEN RI MENJADI PENERIMA PERTAMA VAKSIN BOOSTER INDOVAC

Presiden Joko Widodo menjadi yang pertama menerima vaksin Indovac sebagai vaksin COVID-19 booster-2 di Istana Bogor. Acara penyuntikan dihadiri oleh para Menteri terkait.

RI PRESIDENT BECOMES THE FIRST RECIPIENT OF INDOVAC BOOSTER VACCINE

President Jokowidodo becomes the first to receive the Indovac vaccine as a COVID-19 booster-2 at the Bogor Palace. The injection event was attended by relevant ministers.



KERJASAMA TRANSFER TEKNOLOGI DENGAN MSD

Bio Farma mendatangkan perjanjian kerangka kerja terkait kerjasama transfer teknologi dengan MSD (nama dagang Merck & Co., Inc., Rah-way, N.J., USA) untuk memproduksi secara lokal vaksin 4-valent human papillomavirus (HPV) MSD.

TECHNOLOGY TRANSFER COLLABORATION WITH MSD

Bio Farma signs a framework agreement for technology transfer collaboration with Merck & Co., Inc., Rahway, NJ, USA (MSD) to produce locally the 4-valent human papillomavirus (HPV) MSD vaccine.



BIO FARMA RAIH SKOR EMPAT IT MATURITY LEVEL BERDASARKAN COBIT (CONTROL OBJECTIVE FOR INFORMATION TECHNOLOGIES)

IT maturity merupakan ukuran kematangan proses manajemen TI organisasi. Dengan melakukan IT Maturity Assessment atau Audit, diketahui sejauh mana proses IT telah dikelola dengan baik berdasarkan standar/framework tata kelola IT.

BIO FARMA ACHIEVES FOUR IT MATURITY LEVEL SCORES BASED ON COBIT (CONTROL OBJECTIVE FOR INFORMATION TECHNOLOGIES)

IT maturity is a measure of the maturity level of an organization's IT management processes. Through IT Maturity Assessment or Audit, it is determined to what extent the IT processes are well-managed based on IT governance standards/frameworks.

